Log in
Rabies is an infectious disease that kills at least 55,000 people annually, primarily in Asia and Africa, with infected dogs being the major source of infection in humans. In a recent rabies epidemic on the Indonesian island of Bali, between Dec 2008 and June 2011, over 130 human deaths occurred, because the actions of the local authorities were not sufficient to control the outbreak. Research undertaken at the University of Glasgow was instrumental in the development of an island-wide canine vaccination strategy between 2010 and 2013. These campaigns controlled the spread of rabies in dogs (villages reporting new cases) and reduced the incidence of human deaths by over 90% compared with the incidence before mass canine vaccination started, in late 2010. As of July 2013, Bali had gone 11 months without a human case of rabies. The research also contributed to advocacy, policy formulation and development of computer-based tools to support rabies control both within Bali and other developing countries.
Rabies is the most lethal known infectious disease and kills 55,000 people annually worldwide, mainly in Africa and Asia; however, it is almost entirely preventable. Effective vaccines for animals and humans are available, but their use is limited by cost and accessibility. Research undertaken at the University of Glasgow by Professor Sarah Cleaveland and her team has led to the development and adoption of new health and veterinary policies in East Africa, transforming research findings into practical strategies for rabies prevention and control. These strategies reduce the cost of medical treatment (such as post-exposure prophylaxis), increase its effectiveness (by improving compliance) and eliminate the barriers to receiving treatment in some of the world's most disadvantaged communities. Research by the Glasgow team on dog vaccination strategies has also made a major contribution to the recognition by the World Health Organization (WHO) that global canine rabies elimination is feasible, with national and global strategies now focussing on dog vaccination as a cost effective means of reducing human rabies deaths.
RVC research has helped transform differential diagnosis of canine heart disease, in first opinion veterinary practice, by demonstrating the value of peptide biomarkers and collaborating with diagnostics companies to ensure the findings have been translated into commercial assay kits available around the world. Contributions to major clinical trials have complemented this through improvements in canine cardiac disease treatment. This has benefitted dogs and their owners through improved and prolonged canine health; and has additionally delivered new guidance for professional practice, and economic value through increased therapeutic product sales and novel diagnostic services.
Research led by Dr Watson has demonstrated that chronic pancreatitis (CP) is more common and clinically significant in dogs than veterinary surgeons previously recognised, with strong breed predispositions. Prior to this work, the veterinary profession believed that dogs had a single attack of acute pancreatitis which did not result in the development of exocrine pancreatic insufficiency (EPI) and/or endocrine insufficiency (diabetes mellitus (DM)). The work by Watson has shown the importance of chronic disease and has altered the long term treatment of affected dogs across the profession. It has also prompted companies in the UK, Europe and the USA to increase their focus on low-fat dietary management, pancreatic enzyme supplementation and analgesia improving the quality of life of affected dogs.